Hims & Hers Health, a digital pharmacy startup, has announced its expansion into weight loss treatments with the introduction of access to compounded GLP-1 weight loss injections. The company, which already offers products for erectile dysfunction and hair loss, is currently offering compounded versions of these medications starting at $199 a month. While branded GLP-1 medications will eventually be available, customers can obtain these injections with a prescription from a licensed healthcare provider on the Hims & Hers platform.
In its fourth-quarter earnings report, Hims & Hers projected that its weight loss program would generate over $100 million in revenue by 2025. The GLP-1 market, primarily controlled by Novo Nordisk, has experienced supply challenges due to increasing demand and regulatory approvals. These medications work by mimicking a gut hormone to reduce appetite and regulate blood sugar. The FDA has cautioned against using compounded versions if an approved drug is available, such as Wegovy.
Despite these challenges, CEO Andrew Dudum expressed confidence in the company’s ability to provide a consistent supply of compounded GLP-1 medications. He stated that Hims & Hers has partnered with a reputable generic manufacturer with FDA oversight to ensure reliable production. This partnership includes exclusive access to the manufacturer’s facilities, guaranteeing a steady volume of medication for consumers. Dudum emphasized the company’s commitment to quality and accessibility in expanding its product offerings.
Overall, Hims & Hers’ entry into the weight loss market represents an exciting opportunity for consumers seeking safe and effective weight loss solutions. With its focus on quality and customer service, the company is well positioned to capture a significant share of this growing market.
